
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7972672/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature Communications, 2022, 13, 1878.	12.8	3
2	Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. European Urology, 2021, 79, 16-19.	1.9	36
3	Caught in the net: Characterizing how testicular cancer patients use the internet as an information source. Canadian Urological Association Journal, 2021, 15, E400-E404.	0.6	2
4	Plasma exosome microRNAs in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab: Potential biomarkers of response to therapy Journal of Clinical Oncology, 2021, 39, 338-338.	1.6	0
5	Longer follow-up data of circulating miR371a-3p expression across the spectrum of germ cell tumors (GCT) Journal of Clinical Oncology, 2021, 39, 379-379.	1.6	2
6	Editorial Comment. Journal of Urology, 2021, 205, 717-717.	0.4	0
7	Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clinical Cancer Research, 2021, 27, 4610-4623.	7.0	41
8	The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review. Oncologist, 2021, 26, e1381-e1394.	3.7	8
9	Urinary Large Cell Neuroendocrine Carcinoma. American Journal of Surgical Pathology, 2021, 45, 1399-1408.	3.7	11
10	Small cell carcinoma of the bladder: A population-based analysis of long-term outcomes after radical cystectomy and bladder conservation with chemoradiotherapy. Canadian Urological Association Journal, 2021, 16, .	0.6	0
11	Effectiveness of first-line abiraterone versus enzalutamide amongÂpatients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score–weighted comparative cohort study. European Journal of Cancer, 2021, 152, 215-222.	2.8	11
12	CRAFT—A Proposed Framework for Decentralized Clinical Trials Participation in Canada. Current Oncology, 2021, 28, 3857-3865.	2.2	22
13	Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors. Urology Case Reports, 2021, 39, 101762.	0.3	0
14	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nature Communications, 2021, 12, 184.	12.8	85
15	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2020, 21, 1574-1588.	10.7	324
16	Clinical characteristics and outcomes for young patients with advanced urothelial carcinoma. Canadian Urological Association Journal, 2020, 15, E123-E126.	0.6	0
17	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. Canadian Urological Association Journal, 2020, 14, E373-E382.	0.6	8
18	A fountain of knowledge? The quality of online resources for testicular cancer patients. Canadian Urological Association Journal, 2020, 14, E363-E368.	0.6	4

#	Article	IF	CITATIONS
19	Current Management of Localized Muscle-Invasive Bladder Cancer: AÂConsensus Guideline from the Genitourinary Medical Oncologists ofÂCanada. Bladder Cancer, 2020, 6, 363-392.	0.4	1
20	Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer. Npj Genomic Medicine, 2020, 5, 12.	3.8	9
21	Assembling a network to promote translational bladder cancer research in Canada. Canadian Urological Association Journal, 2020, 14, E475-E481.	0.6	1
22	Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC). Annals of Oncology, 2019, 30, v376.	1.2	0
23	Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy. Annals of Oncology, 2019, 30, v399.	1.2	1
24	Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncology, The, 2019, 20, 1730-1739.	10.7	227
25	Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. Journal of Clinical Oncology, 2019, 37, 3090-3098.	1.6	81
26	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. Canadian Urological Association Journal, 2019, 13, 318-327.	0.6	8
27	Second-Line Systemic Therapies for Metastatic Urothelial Carcinoma: A Population-Based Cohort Analysis. Current Oncology, 2019, 26, 260-265.	2.2	3
28	A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. Clinical Genitourinary Cancer, 2019, 17, 201-208.e1.	1.9	29
29	Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. European Urology, 2019, 75, 940-947.	1.9	60
30	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. European Journal of Cancer, 2019, 108, 69-77.	2.8	25
31	Clinical effectiveness of docetaxel for castrationâ€sensitive prostate cancer in a realâ€world populationâ€based analysis. Prostate, 2019, 79, 281-287.	2.3	15
32	Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review. Journal of Urology, 2019, 202, 49-56.	0.4	24
33	Circulating tumor DNA in patients with metastatic urothelial cancer: concordance of genomic findings with matched tissue biopsies Journal of Clinical Oncology, 2019, 37, e16036-e16036.	1.6	1
34	Immunogenomic landscape of neuroendocrine small cell prostate cancer Journal of Clinical Oncology, 2019, 37, 217-217.	1.6	5
35	Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma Journal of Clinical Oncology, 2019, 37, 457-457.	1.6	3
36	Validation of plasma miR-371a-3p expression in patients with metastatic and early stage germ cell tumor Journal of Clinical Oncology, 2019, 37, 526-526.	1.6	1

#	Article	IF	CITATIONS
37	The impact of time to metastasis on overall survival in patients with prostate cancer. World Journal of Urology, 2018, 36, 1039-1046.	2.2	27
38	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discovery, 2018, 8, 444-457.	9.4	376
39	Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. European Urology Focus, 2018, 4, 733-736.	3.1	18
40	A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer. Journal of Oncology Pharmacy Practice, 2018, 24, 143-145.	0.9	6
41	Plasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer. Annals of Oncology, 2018, 29, viii323-viii324.	1.2	0
42	Editorial Comment. Journal of Urology, 2018, 200, 1262-1263.	0.4	0
43	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget, 2018, 9, 19861-19873.	1.8	37
44	Circulating miR-371a-3p for the detection of low volume viable germ cell tumor: Expanded pilot data, clinical implications and future study Journal of Clinical Oncology, 2018, 36, 4549-4549.	1.6	8
45	Efficacy and tolerability of first-line abiraterone + prednisone (ABI) versus enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) in men ≥ 80 years: A retrospective cohort study Journal of Clinical Oncology, 2018, 36, 5051-5051.	1.6	5
46	Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating cell-free tumor DNA (ctDNA) Journal of Clinical Oncology, 2018, 36, 260-260.	1.6	1
47	Plasma miR371 for the detection of viable germ cell tumor in testicular cancer patients with enlarging or post chemotherapy residual nodes Journal of Clinical Oncology, 2018, 36, 569-569.	1.6	5
48	A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. Oncotarget, 2018, 9, 8155-8164.	1.8	18
49	Real-world experience with docetaxel for castration-sensitive prostate cancer from a population-based analysis Journal of Clinical Oncology, 2018, 36, 297-297.	1.6	1
50	Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi) Journal of Clinical Oncology, 2018, 36, 277-277.	1.6	0
51	A population-based analysis of the effectiveness of docetaxel for castration-sensitive prostate cancer (CSPC) Journal of Clinical Oncology, 2018, 36, e17026-e17026.	1.6	0
52	Expanding Immunotherapy Options for Bladder Cancer. Urology, 2017, 106, 1-2.	1.0	6
53	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. Clinical Genitourinary Cancer, 2017, 15, 548-555.e3.	1.9	37
54	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, The, 2017, 389, 67-76.	13.7	1,728

#	Article	IF	CITATIONS
55	Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. Annals of Oncology, 2017, 28, 2481-2488.	1.2	24
56	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clinical Cancer Research, 2017, 23, 6487-6497.	7.0	121
57	AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. Journal of Urology, 2017, 197, 135-142.	0.4	106
58	Biological assessment of viable germ cell tumor (VT) in patients (pts) with seminoma (S) and non-seminoma (S) using miR371. Annals of Oncology, 2017, 28, v325.	1.2	1
59	A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Canadian Urological Association Journal, 2017, 12, E47-52.	0.6	13
60	Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer Journal of Clinical Oncology, 2017, 35, 4514-4514.	1.6	3
61	A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209 Journal of Clinical Oncology, 2017, 35, 5021-5021.	1.6	1
62	Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2017, 35, 5036-5036.	1.6	8
63	Dissecting the genomic landscape of metastatic bladder cancer using circulating tumor DNA Journal of Clinical Oncology, 2017, 35, 378-378.	1.6	0
64	Abstract 5397: Characterizing the genomic landscape of bladder cancer with circulating tumor DNA. , 2017, , .		0
65	Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or) Tj ETQq1 1 487.	0.784314 3.5	4 rgBT /Over 23
66	Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis. Annals of Oncology, 2016, 27, vi291.	1.2	2
67	IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC). Annals of Oncology, 2016, 27, vi270.	1.2	8
68	Building the Case for Adjuvant Chemotherapy After Radical Cystectomy. Urology, 2016, 94, 1-2.	1.0	3
69	MP49-01 NEXT GENERATION SEQUENCING OF CELL FREE DNA REVEALS GENOMIC ABERRATIONS IN METASTATIC UROTHELIAL CARCINOMA. Journal of Urology, 2016, 195, .	0.4	0
70	Cisplatin- Versus Non–Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. Clinical Genitourinary Cancer, 2016, 14, 331-340.	1.9	12
71	PD28-04 DETECTION OF ANDROGEN RECEPTOR VARIANT 7 (AR-V7) IN WHOLE BLOOD RNA OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS TREATED WITH ABIRATERONE ACETATE (ABI). Journal of Urology, 2016, 195, .	0.4	3
72	Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). Investigational New Drugs, 2016, 34, 771-776.	2.6	4

#	Article	IF	CITATIONS
73	A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Annals of Oncology, 2016, 27, 454-460.	1.2	142
74	Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC) Journal of Clinical Oncology, 2016, 34, 4532-4532.	1.6	9
75	Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2016, 34, 5059-5059.	1.6	7
76	Correlation of a novel whole blood RT-PCR assay measuring AR-V7 expression with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI) Journal of Clinical Oncology, 2016, 34, 223-223.	1.6	2
77	Correlation of AR-V7 expression in whole blood with efficacy of abiraterone acetate (ABI) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) Journal of Clinical Oncology, 2016, 34, e23075-e23075.	1.6	1
78	2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1â,,¢ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo. European Journal of Cancer, 2015, 51, S525.	2.8	0
79	2535 Clinical outcomes in chemotherapy-naÃ ⁻ ve metastatic castrationresistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) stratified by prognosis. European Journal of Cancer, 2015, 51, S486-S487.	2.8	2
80	Localized prostate cancer presenting as a renal pseudo-tumour. Canadian Urological Association Journal, 2015, 9, 505.	0.6	0
81	A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Investigational New Drugs, 2015, 33, 969-976.	2.6	50
82	Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. Clinical Genitourinary Cancer, 2015, 13, 178-184.	1.9	15
83	Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients. European Urology, 2015, 67, 23-29.	1.9	142
84	Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status. European Urology, 2015, 67, 441-447.	1.9	40
85	First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial Journal of Clinical Oncology, 2015, 33, 4503-4503.	1.6	5
86	Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC) Journal of Clinical Oncology, 2015, 33, 4555-4555.	1.6	3
87	Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy Journal of Clinical Oncology, 2015, 33, 335-335.	1.6	Ο
88	Gene expression profiling to improve prognostic stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy Journal of Clinical Oncology, 2015, 33, e15633-e15633.	1.6	0
89	Characterizing discontinuation and withdrawal from phase III oncology clinical trials Journal of Clinical Oncology, 2015, 33, e17731-e17731.	1.6	0
90	Racial disparities in attrition among oncology clinical trial participants Journal of Clinical Oncology, 2015, 33, 6551-6551.	1.6	0

#	Article	IF	CITATIONS
91	A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer. Canadian Urological Association Journal, 2014, 8, 583.	0.6	7
92	Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. Canadian Urological Association Journal, 2014, 8, 309.	0.6	12
93	Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 501-508.	1.6	31
94	Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 440-446.	1.9	29
95	A retrospective, Canadian multiâ€center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castrationâ€resistant prostate cancer. Prostate, 2014, 74, 1544-1550.	2.3	45
96	Evaluation of Prostate-specific Antigen Response Following Cessation of Abiraterone Acetate: Is There Evidence for a Withdrawal Syndrome?. European Urology, 2014, 65, 504-505.	1.9	6
97	Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) Journal of Clinical Oncology, 2014, 32, 5078-5078.	1.6	3
98	Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) Journal of Clinical Oncology, 2014, 32, 29-29.	1.6	1
99	Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) Journal of Clinical Oncology, 2014, 32, 97-97.	1.6	1
100	Integrated comprehensive high-throughput kinomics profiling and whole exome sequencing of penile squamous cell cancer (PSCC) Journal of Clinical Oncology, 2014, 32, 383-383.	1.6	1
101	Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study Journal of Clinical Oncology, 2014, 32, e15616-e15616.	1.6	Ο
102	Composite chromophobe renal cell carcinoma with sarcomatoid differentiation containing osteosarcoma, chondrosarcoma, squamous metaplasia and associated collecting duct carcinoma: a case report. Analytical and Quantitative Cytopathology and Histopathology, 2014, 36, 235-40.	0.2	3
103	The Future of Systemic Therapies for Localised Prostate Cancer. Clinical Oncology, 2013, 25, 506-513.	1.4	6
104	Targeting the Apoptosis Pathway in Prostate Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 79-89.	2.0	43
105	Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors. Clinical Cancer Research, 2013, 19, 2766-2774.	7.0	147
106	Reduction in serum clusterin is a potential therapeutic biomarker in patients with castrationâ€resistant prostate cancer treated with custirsen. Cancer Medicine, 2013, 2, 468-477.	2.8	18
107	A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2013, 31, 113-113.	1.6	2
108	Incremental costs of prostate cancer trials: Are clinical trials really a burden on a public payer system?. Canadian Urological Association Journal, 2013, 7, 1-6.	0.6	3

#	Article	IF	CITATIONS
109	Results of a phase II study of sunitinib (SU) maintenance after response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2013, 31, 153-153.	1.6	1
110	A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Annals of Oncology, 2012, 23, 53-58.	1.2	35
111	Utilization of Radiation Therapy in Metastatic Castration Resistant Prostate Cancer Following the Introduction of Abiraterone into Clinical Oncology Practice. International Journal of Radiation Oncology Biology Physics, 2012, 84, S361-S362.	0.8	0
112	A Phase II Study of SB939 in Patients (PTS) with Castration Resistant Prostate Cancer (CRPC). Annals of Oncology, 2012, 23, ix304.	1.2	0
113	Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c. Clinical Cancer Research, 2011, 17, 5765-5773.	7.0	120
114	A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors Journal of Clinical Oncology, 2011, 29, 3014-3014.	1.6	15
115	A phase II study of sunitinib (SU) for maintenance therapy in metastatic castration-resistant prostate cancer (mCRPC) after response to docetaxel (D) Journal of Clinical Oncology, 2011, 29, 151-151.	1.6	4
116	The neoadjuvant management of bladder cancer in Canada: A survey of genitourinary medical oncologists Journal of Clinical Oncology, 2011, 29, 285-285.	1.6	3
117	Cost of care for prostate cancer patients: An observational cohort study comparing clinical trials to standard care Journal of Clinical Oncology, 2011, 29, 184-184.	1.6	о
118	Patterns of Practice in Palliative Radiotherapy for Painful Bone Metastases: Impact of a Regional Rapid Access Clinic on Access to Care. International Journal of Radiation Oncology Biology Physics, 2010, 78, 533-538.	0.8	39
119	Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 4247-4254.	1.6	221
120	Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Canadian Urological Association Journal, 2010, 4, 263-267.	0.6	42
121	Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. Journal of Clinical Oncology, 2009, 27, 5794-5799.	1.6	1,751
122	Tolerance of Sunitinib in Dialyzed Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2009, 7, E104-E106.	1.9	11
123	7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC). European Journal of Cancer, Supplement, 2009, 7, 407.	2.2	2
124	CUOG PHASE II RANDOMIZED STUDY OF CUSTIRSEN (OGX-011) COMBINATION THERAPY IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER (CRPC) WHO RELAPSED ON OR WITHIN SIX MONTHS OF 1ST-LINE DOCETAXEL THERAPY. Journal of Urology, 2009, 181, 229-230.	0.4	0
125	7170 Clinical practice guideline impact on referral and treatment rates of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a comparative analysis between two Canadian tertiary care centres. European Journal of Cancer, Supplement, 2009, 7, 444.	2.2	Ο
126	Prostate Cancer With Tertiary Gleason Pattern 5 in Prostate Needle Biopsy. American Journal of Surgical Pathology, 2009, 33, 233-240.	3.7	39

BERNHARD EIGL

#	Article	IF	CITATIONS
127	Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer. Clinical Cancer Research, 2008, 14, 6944-6954.	7.0	71
128	A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy. Journal of Clinical Oncology, 2008, 26, 5002-5002.	1.6	24
129	Do clinical practice guidelines (CPGs) change clinical practice? An analysis of CPG impact on referral and treatment patterns for neoadjuvant chemotherapy in bladder cancer. Journal of Clinical Oncology, 2008, 26, 5077-5077.	1.6	13
130	A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel. Journal of Clinical Oncology, 2008, 26, 5166-5166.	1.6	11
131	Utilization of Radiotherapy for Palliation of Bone Metastases: A 3-Year Patterns of Practice Study at a Regional Cancer Centre. International Journal of Radiation Oncology Biology Physics, 2007, 69, S93-S94.	0.8	0
132	Palliative Radiotherapy Improves Pain and Reduces Functional Interference in Patients with Painful Bone Metastases: A Quality Assurance Study. Clinical Oncology, 2006, 18, 539-544.	1.4	47
133	Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather Than Sequential Chemohormonal Therapy for Prostate Cancer. Clinical Cancer Research, 2005, 11, 4905-4911.	7.0	63
134	Analytical and Preanalytical Biases in Serum Proteomic Pattern Analysis for Breast Cancer Diagnosis. Clinical Chemistry, 2005, 51, 1525-1528.	3.2	109
135	Preclinical evidence that chemotherapy for prostate cancer should be given at the same time as androgen withdrawal. Journal of Clinical Oncology, 2005, 23, 4617-4617.	1.6	5

136 Cloning and Characterization of cDNA for Adenosine Kinase from Mammalian (Chinese Hamster,) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 3